Glenmark Pharmaceuticals USA has introduced a multiple-dose vial of epinephrine injection.
Glenmark Pharmaceuticals Inc, USA, has launched Epinephrine Injection USP, a bioequivalent and therapeutically equivalent product to the reference listed drug manufactured by BPI Labs, LLC. The product is available in a 30 mg/30 mL (1 mg/mL) Multiple-Dose Vial and is intended for the U.S. market. According to IQVIA sales data, the Epinephrine Injection market had annual sales of approximately USD 67.6 million for the 12 months ending October 2025. This launch expands Glenmark’s institutional product portfolio and reinforces its commitment to providing high-quality, affordable treatment options.
Glenmark Pharmaceuticals Limited is a prominent Indian multinational pharmaceutical company that has been in operation since 1977. The company has grown from its origins in generic medicines and active pharmaceutical ingredients (APIs) to become a research-led global healthcare organization with a presence in over 80 countries. Glenmark’s core therapeutic expertise includes respiratory, dermatology, oncology, cardiovascular, and anti-infective treatments, with multiple R&D centres and manufacturing facilities across India and internationally.
In recent years, Glenmark has diversified into innovative drug development and biosimilars, while maintaining a strong portfolio of branded generics in high-growth markets. The company has also entered strategic collaborations and licensing deals to advance novel therapies, particularly in oncology. Despite facing quality control challenges in some manufacturing facilities, Glenmark continues to pursue a transformation towards a more innovation-centric business model aimed at increasing its branded portfolio and long-term global competitiveness.
The launch of Epinephrine Injection USP is part of Glenmark’s strategy to strengthen its institutional channel presence and improve access to essential medicines. According to Marc Kikuchi, President and Business Head for North America at Glenmark, the launch supports the company’s commitment to providing high-quality, affordable treatment options. With its robust revenue growth and expanding demand in key markets such as North America and Europe, Glenmark is well-positioned to continue its growth and expansion in the global pharmaceutical market.
The US FDA has issued a recall for an antifungal shampoo manufactured by Sun Pharma.
The US Food and Drug Administration (USFDA) has announced a recall of over 17,000 units of antifungal shampoo, Ciclopirox Shampoo, due to manufacturing issues. The recall was initiated by Taro Pharmaceutical Industries, the US arm of Sun Pharma, on December 9. The shampoo is used to treat seborrheic dermatitis, a condition that causes dry, flaky, and itchy skin. The recall was classified as a Class II recall, which means that the product’s use may lead to temporary or medically reversible health consequences, but the likelihood of serious adverse health outcomes is minimal.
The recall was due to “failed impurity/degradation specifications,” according to the USFDA. Taro Pharmaceutical Industries is a private company and a wholly-owned subsidiary of Sun Pharma, which acquired the Israel-based company in a deal valued at $347.73 million last year. Sun Pharma has been the majority shareholder of Taro since 2010. Taro primarily focuses on dermatology and produces a wide range of prescription and over-the-counter products.
The recall is a setback for Sun Pharma, which is a leading exporter to the US market. In the second quarter of FY26, the company reported revenue of Rs 14,478 crore, with a net profit of Rs 3,118 crore, a 2.56% increase year-on-year. However, formulation sales in the US declined 4.1% to $496 million. The recall highlights the importance of quality control and regulatory compliance in the pharmaceutical industry.
The USFDA’s Enforcement Report noted that the recall was nationwide and affected 17,664 units of the Ciclopirox Shampoo. The company has taken prompt action to address the issue, and the recall is expected to minimize any potential harm to consumers. The incident serves as a reminder of the need for pharmaceutical companies to maintain high standards of quality and manufacturing practices to ensure the safety and efficacy of their products.
Zydus Lifesciences Partners with Myriad Genetics to Introduce Cutting-Edge Cancer Diagnostic Solutions in India.
Zydus Lifesciences Limited, a global life sciences company, has partnered with US-based Myriad Genetics to introduce advanced cancer-risk assessment and prognostic diagnostic tests in India. The exclusive agreement allows Zydus to offer Myriad’s MyRisk Hereditary Cancer Test, MyChoice HRD Plus Test, and Prolaris Prostate Cancer Prognostic Test to patients, clinicians, and healthcare institutions across the country. These tests provide actionable insights into hereditary risk, disease progression, and treatment planning, enabling personalized and evidence-based cancer care.
The MyRisk test helps individuals and families understand genetic cancer risk, enabling informed lifestyle choices and monitoring. The Prolaris and MyChoice HRD Plus tests provide clinically validated insights that guide treatment selection and predict disease progression for patients with prostate and ovarian cancers. With cancer incidence rising worldwide, early identification of inherited risk plays a critical role in prevention and proactive health management.
Dr. Sharvil P Patel, Managing Director of Zydus Lifesciences, stated that the partnership represents a significant step toward improving access to precision diagnostics in India. The tests offer clinicians valuable tools to personalize treatment strategies, assess disease aggressiveness, and streamline clinical decision-making, ultimately helping patients achieve better outcomes. The collaboration reflects Zydus’ continued focus on patient-centric care and precision oncology.
Brian Donnelly, Chief Commercial Officer of Myriad Genetics, emphasized that the collaboration with Zydus will help expand the reach of precision oncology solutions across India. Myriad’s tests are designed to equip clinicians with clear, actionable insights into genetic risk and tumor biology, supporting personalized care and informed treatment decisions. The Prolaris test, in particular, offers a clinically proven method to assess disease aggressiveness and guide treatment choices for prostate cancer patients.
Zydus Lifesciences Limited is an innovation-led life sciences company with a strong presence in pharmaceuticals, consumer wellness, and MedTech. The company operates globally, employing over 29,000 people, including a robust R&D workforce dedicated to advancing healthcare solutions. Myriad Genetics is a global leader in molecular diagnostics and precision medicine, developing tests that assess disease risk, predict progression, and guide treatment decisions across multiple medical specialties. The partnership aims to support earlier and more accurate cancer risk assessment, enabling patients to make informed decisions with greater confidence.
Zydus Lifesciences Partners to Introduce Diagnostic Tests for Cancer Risk Evaluation in Indian Market
Zydus Lifesciences Limited is a global life sciences company based in India that is involved in the discovery, development, manufacture, and marketing of a wide range of healthcare therapies. The company operates in the business of integrated pharmaceutical operations, offering a diverse product portfolio that includes active pharmaceutical ingredients (API), human formulations, animal health and veterinary products, as well as health and wellness products.
The company’s product portfolio is categorized into several segments, including India formulations, generics, and Zydus biologics. Some of its notable products include Lipaglyn and Bilypsa (Saroglitazar), which are used to treat various health conditions. Additionally, the company offers a range of biosimilars, such as Ujvira (Trastuzumab emtansine biosimilar), Exemptia (Adalimumab biosimilar), Vivitra (Trastuzumab biosimilar), and Bryxta (Bevacizumab biosimilar), which are used to treat various diseases, including cancer and autoimmune disorders.
Zydus biologics, a key segment of the company, covers a wide range of therapeutic areas, including oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology, and infectious illnesses, among others. The company’s products are designed to provide effective treatment options for patients with various health conditions, and its biosimilars are developed to be more affordable and accessible alternatives to traditional biologic therapies.
With a global presence, Zydus Lifesciences Limited markets its products in several key regions, including the United States, India, Europe, and emerging markets. The company’s global reach and diverse product portfolio have established it as a significant player in the global life sciences industry. Through its commitment to innovation and quality, Zydus Lifesciences Limited aims to provide effective and affordable healthcare solutions to patients around the world. Overall, the company’s broad range of products and global presence have positioned it for continued growth and success in the life sciences industry.
No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.